0.2803 USD
+0.02 (+6.98%)
CODX gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 187 industry peers in the Health Care Equipment & Supplies industry. No worries on liquidiy or solvency for CODX as it has an excellent financial health rating, but there are worries on the profitability. CODX is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year CODX has reported negative net income.
CODX had a negative operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: CODX reported negative net income in multiple years.
In multiple years CODX reported negative operating cash flow during the last 5 years.
1.2 Ratios
CODX has a worse Return On Assets (-71.93%) than 74.33% of its industry peers.
CODX has a Return On Equity of -80.80%. This is in the lower half of the industry: CODX underperforms 60.43% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -71.93% | ||
| ROE | -80.8% | ||
| ROIC | N/A |
ROA(3y)-35.82%
ROA(5y)-4.97%
ROE(3y)-40.94%
ROE(5y)-6.37%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
CODX's Gross Margin of 34.04% is on the low side compared to the rest of the industry. CODX is outperformed by 74.33% of its industry peers.
CODX's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for CODX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 34.04% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.47%
GM growth 5Y9.36%
2. Health
2.1 Basic Checks
CODX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CODX has been increased compared to 1 year ago.
Compared to 5 years ago, CODX has more shares outstanding
CODX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
Based on the Altman-Z score of -2.08, we must say that CODX is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of CODX (-2.08) is comparable to the rest of the industry.
CODX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -2.08 |
ROIC/WACCN/A
WACC8.79%
2.3 Liquidity
CODX has a Current Ratio of 3.81. This indicates that CODX is financially healthy and has no problem in meeting its short term obligations.
CODX's Current ratio of 3.81 is fine compared to the rest of the industry. CODX outperforms 66.31% of its industry peers.
A Quick Ratio of 3.51 indicates that CODX has no problem at all paying its short term obligations.
The Quick ratio of CODX (3.51) is better than 69.52% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.81 | ||
| Quick Ratio | 3.51 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 22.05% over the past year.
CODX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -93.06%.
Measured over the past years, CODX shows a very strong growth in Revenue. The Revenue has been growing by 79.52% on average per year.
EPS 1Y (TTM)22.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
Revenue 1Y (TTM)-93.06%
Revenue growth 3Y-65.8%
Revenue growth 5Y79.52%
Sales Q2Q%-77.38%
3.2 Future
The Earnings Per Share is expected to grow by 28.59% on average over the next years. This is a very strong growth
CODX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 171.12% yearly.
EPS Next Y36.81%
EPS Next 2Y27.84%
EPS Next 3Y17.9%
EPS Next 5Y28.59%
Revenue Next Year-88.3%
Revenue Next 2Y-62.71%
Revenue Next 3Y60.7%
Revenue Next 5Y171.12%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
CODX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CODX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as CODX's earnings are expected to grow with 17.90% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.84%
EPS Next 3Y17.9%
5. Dividend
5.1 Amount
No dividends for CODX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:CODX (12/18/2025, 2:09:11 PM)
0.2803
+0.02 (+6.98%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners18.29%
Inst Owner Change8.83%
Ins Owners5.87%
Ins Owner Change5.92%
Market Cap17.07M
Revenue(TTM)507.90K
Net Income(TTM)-32.18M
Analysts80
Price Target1.27 (353.09%)
Short Float %1.99%
Short Ratio0.04
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)32.8%
Min EPS beat(2)1.96%
Max EPS beat(2)63.63%
EPS beat(4)3
Avg EPS beat(4)22.62%
Min EPS beat(4)-3.81%
Max EPS beat(4)63.63%
EPS beat(8)5
Avg EPS beat(8)-4.35%
EPS beat(12)7
Avg EPS beat(12)-30.05%
EPS beat(16)10
Avg EPS beat(16)-21.09%
Revenue beat(2)1
Avg Revenue beat(2)0.65%
Min Revenue beat(2)-5.23%
Max Revenue beat(2)6.54%
Revenue beat(4)1
Avg Revenue beat(4)-36.65%
Min Revenue beat(4)-86.85%
Max Revenue beat(4)6.54%
Revenue beat(8)3
Avg Revenue beat(8)53.36%
Revenue beat(12)4
Avg Revenue beat(12)112.38%
Revenue beat(16)5
Avg Revenue beat(16)77.24%
PT rev (1m)-37.5%
PT rev (3m)-77.27%
EPS NQ rev (1m)4%
EPS NQ rev (3m)4%
EPS NY rev (1m)4.76%
EPS NY rev (3m)4.11%
Revenue NQ rev (1m)-16%
Revenue NQ rev (3m)-16%
Revenue NY rev (1m)-5.56%
Revenue NY rev (3m)-5.56%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 33.6 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.43 | ||
| P/tB | 1.24 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.99
EYN/A
EPS(NY)-0.41
Fwd EYN/A
FCF(TTM)-0.52
FCFYN/A
OCF(TTM)-0.51
OCFYN/A
SpS0.01
BVpS0.65
TBVpS0.23
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -71.93% | ||
| ROE | -80.8% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 34.04% | ||
| FCFM | N/A |
ROA(3y)-35.82%
ROA(5y)-4.97%
ROE(3y)-40.94%
ROE(5y)-6.37%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.47%
GM growth 5Y9.36%
F-Score2
Asset Turnover0.01
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 53.59% | ||
| Cap/Sales | 126.23% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.81 | ||
| Quick Ratio | 3.51 | ||
| Altman-Z | -2.08 |
F-Score2
WACC8.79%
ROIC/WACCN/A
Cap/Depr(3y)92.34%
Cap/Depr(5y)204.81%
Cap/Sales(3y)14.45%
Cap/Sales(5y)9.01%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)22.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
EPS Next Y36.81%
EPS Next 2Y27.84%
EPS Next 3Y17.9%
EPS Next 5Y28.59%
Revenue 1Y (TTM)-93.06%
Revenue growth 3Y-65.8%
Revenue growth 5Y79.52%
Sales Q2Q%-77.38%
Revenue Next Year-88.3%
Revenue Next 2Y-62.71%
Revenue Next 3Y60.7%
Revenue Next 5Y171.12%
EBIT growth 1Y11.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-41.31%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-46.26%
OCF growth 3YN/A
OCF growth 5YN/A
CO-DIAGNOSTICS INC / CODX FAQ
What is the ChartMill fundamental rating of CO-DIAGNOSTICS INC (CODX) stock?
ChartMill assigns a fundamental rating of 3 / 10 to CODX.
Can you provide the valuation status for CO-DIAGNOSTICS INC?
ChartMill assigns a valuation rating of 0 / 10 to CO-DIAGNOSTICS INC (CODX). This can be considered as Overvalued.
How profitable is CO-DIAGNOSTICS INC (CODX) stock?
CO-DIAGNOSTICS INC (CODX) has a profitability rating of 1 / 10.
Can you provide the expected EPS growth for CODX stock?
The Earnings per Share (EPS) of CO-DIAGNOSTICS INC (CODX) is expected to grow by 36.81% in the next year.